Evidence map›Paper›PMID 16905679›Full record

ArticleJournal of medical genetics2007

Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation.

Hayley Archer, Julie Evans, Helen Leonard, Lyn Colvin, David Ravine, John Christodoulou, Sarah Williamson, Tony Charman, Mark E S Bailey, Julian Sampson and 2 more

2 registry-linked trialsOpen access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Journal of medical genetics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02705677 completednot on this mapstarted 2017, after this paper: background citation

Biobanking of Rett Syndrome and Related Disorders Protocol

TypeobservationalSponsorUniversity of Alabama at BirminghamRan2017 to 2021Enrolled752ConditionsRett Syndrome, MECP2 Duplication, CDKL5, FOXG1 Disorders
NCT02738281 completednot on this mapstarted 2015, after this paper: background citation

Rett Syndrome, MECP2 Duplication Disorder, and Rett- Related Disorders Natural History Protocol

TypeobservationalSponsorUniversity of Alabama at BirminghamRan2015 to 2021Enrolled1,044ConditionsRett Syndrome, MECP2 Duplication dIsorder, CDKL5 Disorder, FOXG1 Syndrome
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Rett syndrome.Nature reviews. Disease primers · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Dental Pulp-Derived Mesenchymal Stem Cells for Modeling Genetic Disorders.International journal of molecular sciences · 2021
    Review
  18. Review
  19. X-chromosome regulation and sex differences in brain anatomy.Neuroscience and biobehavioral reviews · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Hayley ArcherInstitute of Medical Genetics, Cardiff University, University Hospital of Wales, Cardiff, UK.
Julie Evans
Helen Leonard
Lyn Colvin
David Ravine
John Christodoulou
Sarah Williamson
Tony Charman
Mark E S Bailey
Julian Sampson
Nicholas de Klerk
Angus Clarke
University of Western Australia · AUCardiff University · GBUniversity Hospital of Wales · GBChildren's Hospital at Westmead · AUUniversity College London · GBUniversity of Glasgow · GBUniversity of Sydney · AU

Funding

Rett syndrome: determinants of outcome and burdenR01HD043100 · NICHD · UNIVERSITY OF WESTERN AUSTRALIA · PI LEONARD, HELEN M · 2003 to 2007
$838k
NICHD NIH HHS 1 R01 HD43100-01A1NICHD NIH HHS R01 HD043100
6 · The paper itself

Abstract

introductionRett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder that is usually associated with mutations in the MECP2 gene. The most common mutations in the gene are p.R168X and p.T158M. The influence of X-chromosome inactivation (XCI) on clinical severity in patients with RTT with these mutations was investigated, taking into account the extent and direction of skewing.

methodsFemale patients and their parents were recruited from the UK and Australia. Clinical severity was measured by the Pineda Severity and Kerr profile scores. The degree of XCI and its direction relative to the X chromosome parent of origin were measured in DNA prepared from peripheral blood leucocytes, and allele-specific polymerase chain reaction was used to determine the parental origin of mutation. Combining these, the percentage of cells expected to express the mutant allele was calculated.

resultsLinear regression analysis was undertaken for fully informative cases with p.R168X (n = 23) and p.T158M (n = 20) mutations. A statistically significant increase in clinical severity with increase in the proportion of active mutated allele was shown for both the p.R168X and p.T158M mutations.

conclusionsXCI may vary in neurological and haematological tissues. However, these data are the first to show a relationship between the degree and direction of XCI in leucocytes and clinical severity in RTT, although the clinical utility of this in giving a prognosis for individual patients is unclear.

Indexed as

MutationX Chromosome InactivationAmino Acid SubstitutionAustraliaHumansMethyl-CpG-Binding Protein 2Rett SyndromeScotlandSeverity of Illness IndexWalesMECP2 protein, humanMethyl-CpG-Binding Protein 2

Identifiers

PMID16905679
PMCPMC2598067
OpenAlexW2129654526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.